Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progestin therapy of breast cancer: comparison of agents.

× No keyword cloud information.

15 in total

1. THE EXCRETION OF OESTRONE, PREGNANEDIOL AND PREGNANETRIOL IN BREAST CANCER PATIENTS. I. EXCRETION AFTER SPONTANEOUS MENOPAUSE.

Authors: R NISSEN-MEYER; T SANNER
Journal: Acta Endocrinol (Copenh) Date: 1963-11

2. The histology of induced mammary tumours in rats.

Authors: S YOUNG; D M COWAN; L E SUTHERLAND
Journal: J Pathol Bacteriol Date: 1963-04

3. Clinical and pharmacological observations of the effects of 9-alpha-bromo-11-beta-ketoprogesterone in patients with carcinoma of the breast.

Authors: U JONSSON; J COLSKY; H E LESSNER; O S ROATH; R G ALPER; R JONES
Journal: Cancer Date: 1959 May-Jun Impact factor: 6.860

4. Studies with 19-norethisterone oenanthate in mammary carcinoma.

Authors: M DOUGLAS; J A LORAINE; J A STRONG
Journal: Proc R Soc Med Date: 1960-06

5. Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone.

Authors: C HUGGINS; R C MOON; S MORII
Journal: Proc Natl Acad Sci U S A Date: 1962-03-15 Impact factor: 11.205

6. Post-menopausal oestrogen production.

Authors: R A STRUTHERS
Journal: Br Med J Date: 1956-06-09

7. Clinical investigative experience with steroid hormones in breast cancer.

Authors: I T NATHANSON
Journal: Cancer Date: 1952-07 Impact factor: 6.860

8. Probable mode of action of oral contraceptives.

Authors: E Diczfalusy
Journal: Br Med J Date: 1965-12-11

9. Pituitary function and hormonal therapy of experimental breast cancer.

Authors: U Kim
Journal: Cancer Res Date: 1965-08 Impact factor: 12.701

10. Progesterone in the treatment of advanced malignant tumours of breast, ovary and uterus.

Authors: B JOLLES
Journal: Br J Cancer Date: 1962-06 Impact factor: 7.640

11 in total

Review 1. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors: P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal: Clin Pharmacokinet Date: 1992-05 Impact factor: 6.447

Review 2. Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

Authors: A D Stockdale; A Y Rostom
Journal: Clin Pharmacokinet Date: 1989-03 Impact factor: 6.447

3. High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors: M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

Review 4. Current status of the management of patients with endocrine-sensitive tumors. I. Introduction and carcinoma of the breast.

Authors: L G Crowley
Journal: Calif Med Date: 1969-01

Review 5. Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors: Shawna B Matthews; Carol A Sartorius
Journal: Horm Cancer Date: 2016-10-28 Impact factor: 3.869

6. Megestrol acetate: phase II study of a single daily administration in advanced breast cancer.

Authors: P Pronzato; F Brema; D Amoroso; G Bertelli; P F Conte; M C Martini; G Pastorino; R Rosso
Journal: Breast Cancer Res Treat Date: 1990-11 Impact factor: 4.872

7. [Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies].

Authors: H E Wander; H C Blossey; G A Nagel; D Emrich
Journal: Klin Wochenschr Date: 1985-04-01

8. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Authors: M Salimtschik; H T Mouridsen; J Loeber; E Johansson
Journal: Cancer Chemother Pharmacol Date: 1980 Impact factor: 3.333

9. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Authors: D W Hedley; M Christie; R P Weatherby; I D Caterson
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

10. Growth regulation of two rat adenocarcinoma cell lines by dexamethasone and progesterone.

Authors: E Joly; F Vignon; H Rochefort
Journal: Breast Cancer Res Treat Date: 1981 Impact factor: 4.872